Ablative and Immunostimulatory Effects of Histotripsy Ablation in a Murine Osteosarcoma Model

Author:

Hay Alayna N.1,Imran Khan Mohammad23ORCID,Hendricks-Wenger Alissa234ORCID,Gannon Jessica M.4,Sereno Jacqueline2,Simon Alex4,Lopez Victor A.4,Coutermarsh-Ott Sheryl25,Vlaisavljevich Eli4,Allen Irving C.23,Tuohy Joanne L.1ORCID

Affiliation:

1. Department of Small Animal Clinical Sciences, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA 24061, USA

2. Department of Biomedical Sciences and Pathobiology, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA 24061, USA

3. Translational Biology, Medicine and Health Graduate Research Program, Virginia Tech, Roanoke, VA 24016, USA

4. Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA 24061, USA

5. Virginia Department of Agriculture and Consumer Services, Wytheville, VA 24382, USA

Abstract

Background: Osteosarcoma (OS) is the most frequently occurring malignant bone tumor in humans, primarily affecting children and adolescents. Significant advancements in treatment options for OS have not occurred in the last several decades, and the prognosis remains grim with only a 70% rate of 5-year survival. The objective of this study was to investigate the focused ultrasound technique of histotripsy as a novel, noninvasive treatment option for OS. Methods: We utilized a heterotopic OS murine model to establish the feasibility of ablating OS tumors with histotripsy in a preclinical setting. We investigated the local immune response within the tumor microenvironment (TME) via immune cell phenotyping and gene expression analysis. Findings: We established the feasibility of ablating heterotopic OS tumors with ablation characterized microscopically by loss of cellular architecture in targeted regions of tumors. We observed greater populations of macrophages and dendritic cells within treated tumors and the upregulation of immune activating genes 72 h after histotripsy ablation. Interpretation: This study was the first to investigate histotripsy ablation for OS in a preclinical murine model, with results suggesting local immunomodulation within the TME. Our results support the continued investigation of histotripsy as a novel noninvasive treatment option for OS patients to improve clinical outcomes and patient prognosis.

Funder

Foundation for the National Institutes of Health

Publisher

MDPI AG

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Reference63 articles.

1. Osteosarcoma: A comprehensive review;Misaghi;SICOT J.,2018

2. Osteosarcoma: A Meta-Analysis and Review of the Literature;Friebele;Am. J. Orthop.,2015

3. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons;Mirabello;Int. J. Cancer,2009

4. Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes;Nie;Oncol. Lett.,2018

5. Moukengue, B., Lallier, M., Marchandet, L., Baud’huin, M., Verrecchia, F., Ory, B., and Lamoureux, F. (2022). Origin and Therapies of Osteosarcoma. Cancers, 14.

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3